Sanne B Schagen

Summary

Affiliation: The Netherlands Cancer Institute
Country: The Netherlands

Publications

  1. ncbi Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer
    Sanne B Schagen
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Acta Oncol 47:63-70. 2008
  2. ncbi Information about chemotherapy-associated cognitive problems contributes to cognitive problems in cancer patients
    Sanne B Schagen
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Psychooncology 21:1132-5. 2012
  3. ncbi Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy
    Vincent Koppelmans
    Erasmus MC University Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 30:1080-6. 2012
  4. ncbi Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial
    Christina M Schilder
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Amsterdam, The Netherlands
    J Clin Oncol 28:1294-300. 2010
  5. ncbi The influence of priming and pre-existing knowledge of chemotherapy-associated cognitive complaints on the reporting of such complaints in breast cancer patients
    Sanne B Schagen
    Department of Psychosocial Research and Epidemiology of the Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam The Netherlands
    Psychooncology 18:674-8. 2009
  6. ncbi Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients
    Sanne B Schagen
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan121, 1066 CX Amsterdam, The Netherlands
    J Natl Cancer Inst 98:1742-5. 2006
  7. ncbi Cognitive dysfunction in people with cancer
    Sanne B Schagen
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
    Lancet Oncol 8:852-3. 2007
  8. ncbi Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study
    Christina M Schilder
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    Acta Oncol 48:76-85. 2009
  9. ncbi ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy
    Baudewijntje P C Kreukels
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Clin Neurophysiol 119:533-41. 2008
  10. ncbi Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer
    Baudewijntje P C Kreukels
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Clin Breast Cancer 8:80-7. 2008

Collaborators

Detail Information

Publications19

  1. ncbi Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer
    Sanne B Schagen
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Acta Oncol 47:63-70. 2008
    ..This study examined the prevalence of cognitive complaints and deficits in testicular cancer (TC) patients treated with the worldwide standard BEP (bleomycin, etoposide and cisplatin) chemotherapy...
  2. ncbi Information about chemotherapy-associated cognitive problems contributes to cognitive problems in cancer patients
    Sanne B Schagen
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Psychooncology 21:1132-5. 2012
    ....
  3. ncbi Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy
    Vincent Koppelmans
    Erasmus MC University Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 30:1080-6. 2012
    ..We investigated whether cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy for breast cancer is associated with worse cognitive performance more than 20 years after treatment...
  4. ncbi Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial
    Christina M Schilder
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Amsterdam, The Netherlands
    J Clin Oncol 28:1294-300. 2010
    ..To evaluate the influence of adjuvant tamoxifen and exemestane on cognitive functioning in postmenopausal patients with breast cancer (BC)...
  5. ncbi The influence of priming and pre-existing knowledge of chemotherapy-associated cognitive complaints on the reporting of such complaints in breast cancer patients
    Sanne B Schagen
    Department of Psychosocial Research and Epidemiology of the Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam The Netherlands
    Psychooncology 18:674-8. 2009
    ..We examined whether pre-existing knowledge of chemotherapy-associated cognitive problems and priming the 'chemo-brain' schema increase the reporting of cognitive complaints...
  6. ncbi Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients
    Sanne B Schagen
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan121, 1066 CX Amsterdam, The Netherlands
    J Natl Cancer Inst 98:1742-5. 2006
    ..2, 95% CI = 0.5 to 9.1, P = .27; no-CT versus Control: OR = 2.2, 95% CI = 0.6 to 8.0; P = .21). Some cytotoxic treatment for breast cancer affects cognition in a subset of women...
  7. ncbi Cognitive dysfunction in people with cancer
    Sanne B Schagen
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
    Lancet Oncol 8:852-3. 2007
  8. ncbi Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study
    Christina M Schilder
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    Acta Oncol 48:76-85. 2009
    ....
  9. ncbi ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy
    Baudewijntje P C Kreukels
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Clin Neurophysiol 119:533-41. 2008
    ..The aim of the present study was to examine the effects of various regimens of adjuvant chemotherapy on the N1 and P3 component of the event-related potential (ERP) in breast cancer patients 3-6 years after treatment...
  10. ncbi Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer
    Baudewijntje P C Kreukels
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Clin Breast Cancer 8:80-7. 2008
    ..The present study aims to combine the results of neuropsychological and electrophysiological techniques collected in patients with breast cancer treated with cyclophosphamide/methotrexate/5-fluorouracil (CMF) at different time points...
  11. ncbi Incidental findings on brain Magnetic Resonance Imaging in long-term survivors of breast cancer treated with adjuvant chemotherapy
    Vincent Koppelmans
    Erasmus University Medical Center, Department of Epidemiology, Plesmanlaan 121, Rotterdam, The Netherlands
    Eur J Cancer 47:2531-6. 2011
    ....
  12. ncbi The impact of different definitions and reference groups on the prevalence of cognitive impairment: a study in postmenopausal breast cancer patients before the start of adjuvant systemic therapy
    Christina M Schilder
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    Psychooncology 19:415-22. 2010
    ..We examined the impact of four different criteria of cognitive impairment and two types of reference groups (a study-specific healthy reference group versus published normative data) on the prevalence of cognitive impairment...
  13. ncbi Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer
    Michiel B de Ruiter
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    Hum Brain Mapp 32:1206-19. 2011
    ....
  14. ncbi Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy
    Baudewijntje P C Kreukels
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Breast Cancer Res Treat 94:53-61. 2005
    ..Our data provide further evidence for long-term neurocognitive problems in breast-cancer patients treated with adjuvant (CMF) chemotherapy and offer new information regarding abnormalities in brain functioning in these patients...
  15. ncbi Cognitive dysfunction and chemotherapy: neuropsychological findings in perspective
    Sanne B Schagen
    Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam
    Clin Breast Cancer 3:S100-8. 2002
    ..Also, future developments necessary to gain more insight into the prevalence, the pattern, and the impact of cognitive problems following chemotherapy are discussed..
  16. ncbi Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging
    Michiel B de Ruiter
    Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    Hum Brain Mapp 33:2971-83. 2012
    ..Using this multimodality approach we provide for the first time insight into the neural substrate underlying cognitive impairments following systemic administration of cytotoxic agents many years after treatment...
  17. ncbi Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat
    Riejanne Seigers
    Department of Behavioral Physiology, University of Groningen, Kerklaan 30, 9750 AA Haren, The Netherlands
    Behav Brain Res 186:168-75. 2008
    ..These findings suggest that adverse effects of certain cytotoxic agents on hippocampal cell proliferation may have a potential contributory role in cognitive impairment observed in humans after chemotherapy...
  18. ncbi Does cognitive impairment after chemotherapy for breast cancer improve over time or does practice make perfect?
    Sanne B Schagen
    J Clin Oncol 24:5170-1; author reply 5171-2. 2006
  19. ncbi Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study
    Baudewijntje P C Kreukels
    Department of Psycho-Social Research and Epidemiology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam
    Clin Breast Cancer 7:67-78. 2006
    ..The observed P3 reduction might be a result of suboptimal phasic cortical arousal and problems with the allocation of processing resources in these patients...